See more : The Blockchain Group (ALTBG.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Lupin Limited (LUPIN.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lupin Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Perk Labs Inc. (PERK.CN) Income Statement Analysis – Financial Results
- Muhibbah Engineering (M) Bhd. (5703.KL) Income Statement Analysis – Financial Results
- PNG Copper Inc. (PNGC.CN) Income Statement Analysis – Financial Results
- NatWest Group plc (RBSPF) Income Statement Analysis – Financial Results
- Companhia Energética do Rio Grande do Norte – COSERN (CSRN6.SA) Income Statement Analysis – Financial Results
Lupin Limited (LUPIN.BO)
About Lupin Limited
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilars; over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 196.56B | 162.70B | 161.93B | 149.27B | 151.43B | 143.18B | 155.52B | 169.93B | 136.34B | 125.86B | 110.89B | 94.50B | 69.51B | 58.19B | 47.74B | 37.76B | 27.06B | 20.14B | 16.95B | 12.61B | 12.15B |
Cost of Revenue | 76.39B | 72.65B | 70.88B | 59.17B | 59.72B | 53.90B | 57.48B | 56.03B | 48.09B | 45.22B | 40.96B | 37.87B | 27.96B | 22.38B | 19.69B | 16.04B | 11.64B | 9.32B | 8.26B | 6.44B | 6.22B |
Gross Profit | 120.17B | 90.05B | 91.05B | 90.10B | 91.71B | 89.28B | 98.04B | 113.90B | 88.25B | 80.64B | 69.93B | 56.63B | 41.55B | 35.81B | 28.04B | 21.72B | 15.43B | 10.82B | 8.69B | 6.17B | 5.93B |
Gross Profit Ratio | 61.14% | 55.35% | 56.23% | 60.36% | 60.56% | 62.35% | 63.04% | 67.03% | 64.73% | 64.07% | 63.06% | 59.93% | 59.78% | 61.54% | 58.74% | 57.51% | 57.00% | 53.71% | 51.28% | 48.93% | 48.78% |
Research & Development | 0.00 | 11.74B | 12.77B | 12.80B | 15.54B | 15.01B | 17.08B | 23.10B | 16.04B | 10.99B | 9.29B | 7.10B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 13.87B | 10.49B | 9.15B | 8.63B | 9.38B | 6.64B | 6.01B | 6.47B | 6.22B | 3.87B | 4.57B | 3.67B | 2.40B | 8.99B | 13.30B | 10.36B | 7.99B | 5.69B | 4.77B | 3.51B | 2.61B |
Selling & Marketing | 12.16B | 10.75B | 9.81B | 9.09B | 9.64B | 10.91B | 10.28B | 9.30B | 7.37B | 7.12B | 6.52B | 6.04B | 5.57B | 5.47B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 95.67B | 21.24B | 18.97B | 17.73B | 19.02B | 17.54B | 16.29B | 15.77B | 13.59B | 10.99B | 11.09B | 9.71B | 7.96B | 14.47B | 13.30B | 10.36B | 7.99B | 5.69B | 4.77B | 3.51B | 2.61B |
Other Expenses | 0.00 | 62.80M | 730.40M | 215.80M | 410.40M | 148.60M | 286.70M | 219.40M | 171.30M | 24.30M | 27.30M | 20.10M | 38.90M | -60.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 95.67B | 81.16B | 85.54B | 72.71B | 77.82B | 72.66B | 77.34B | 75.08B | 56.36B | 47.35B | 41.66B | 36.90B | 29.12B | 25.58B | 19.30B | 15.16B | 9.65B | 6.37B | 6.13B | 4.94B | 3.49B |
Cost & Expenses | 171.44B | 153.81B | 156.42B | 131.88B | 137.54B | 126.56B | 134.83B | 131.12B | 104.45B | 92.57B | 82.63B | 74.77B | 57.08B | 47.96B | 38.99B | 31.20B | 21.29B | 15.69B | 14.39B | 11.38B | 9.72B |
Interest Income | 462.30M | 324.30M | 328.10M | 598.40M | 1.29B | 664.20M | 195.60M | 169.00M | 82.90M | 130.60M | 158.60M | 141.50M | 92.30M | 30.10M | 48.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 3.12B | 2.40B | 1.07B | 1.17B | 3.40B | 2.63B | 1.59B | 1.25B | 403.00M | 55.90M | 99.00M | 240.30M | 278.90M | 344.80M | -336.40M | 498.60M | 373.50M | 372.20M | 312.80M | 282.50M | 0.00 |
Depreciation & Amortization | 9.96B | 8.41B | 8.19B | 8.53B | 9.70B | 8.46B | 10.86B | 9.12B | 4.87B | 4.35B | 2.61B | 3.32B | 2.28B | 1.71B | 1.24B | 879.90M | 647.40M | 466.10M | 408.80M | 336.20M | 295.30M |
EBITDA | 36.97B | 18.05B | -4.39B | 26.48B | 20.32B | 27.57B | 18.17B | 45.87B | 38.53B | 38.59B | 31.18B | 22.98B | 14.55B | 12.00B | 9.98B | 7.44B | 6.42B | 4.91B | 2.98B | 1.57B | 2.73B |
EBITDA Ratio | 18.81% | 11.38% | 14.50% | 17.39% | 19.16% | 20.96% | 20.57% | 28.18% | 27.76% | 30.68% | 28.25% | 24.25% | 20.92% | 20.53% | 20.91% | 19.70% | 23.73% | 24.40% | 17.56% | 12.44% | 22.48% |
Operating Income | 28.04B | 8.32B | 12.86B | 17.14B | 12.17B | 15.09B | 48.69B | 33.54B | 32.62B | 34.26B | 28.72B | 19.60B | 12.27B | 10.23B | 8.74B | 6.56B | 5.78B | 4.45B | 2.57B | 1.23B | 2.44B |
Operating Income Ratio | 14.27% | 5.11% | 7.94% | 11.48% | 8.04% | 10.54% | 31.31% | 19.74% | 23.92% | 27.22% | 25.90% | 20.74% | 17.64% | 17.59% | 18.31% | 17.37% | 21.34% | 22.08% | 15.15% | 9.77% | 20.05% |
Total Other Income/Expenses | -3.82B | -42.29B | -26.58B | -33.95B | -4.60B | -999.20M | -15.23B | 1.89B | -24.57B | 853.60M | 55.50M | -945.60M | -469.30M | -285.80M | -384.90M | -498.60M | -373.50M | -372.20M | -312.80M | -282.50M | -525.90M |
Income Before Tax | 24.22B | 7.16B | -13.72B | 16.76B | 7.57B | 14.09B | 5.47B | 35.43B | 33.29B | 34.15B | 28.32B | 19.25B | 11.96B | 9.94B | 8.36B | 6.06B | 5.40B | 4.07B | 2.26B | 949.60M | 1.91B |
Income Before Tax Ratio | 12.32% | 4.40% | -8.47% | 11.23% | 5.00% | 9.84% | 3.52% | 20.85% | 24.42% | 27.13% | 25.54% | 20.37% | 17.21% | 17.09% | 17.51% | 16.05% | 19.96% | 20.23% | 13.30% | 7.53% | 15.73% |
Income Tax Expense | 4.87B | 2.69B | 1.37B | 4.49B | 11.57B | 8.88B | 2.88B | 9.79B | 10.59B | 9.70B | 9.62B | 5.84B | 3.09B | 1.15B | 1.36B | 983.00M | 1.32B | 988.10M | 521.00M | 27.40M | 518.00M |
Net Income | 19.14B | 4.30B | -15.28B | 12.17B | -2.69B | 6.07B | 2.51B | 25.57B | 22.61B | 24.03B | 18.36B | 13.14B | 8.68B | 8.63B | 6.82B | 5.02B | 4.08B | 3.09B | 1.73B | 918.40M | 1.39B |
Net Income Ratio | 9.74% | 2.64% | -9.44% | 8.15% | -1.78% | 4.24% | 1.62% | 15.05% | 16.58% | 19.09% | 16.56% | 13.91% | 12.48% | 14.82% | 14.28% | 13.28% | 15.08% | 15.32% | 10.20% | 7.28% | 11.46% |
EPS | 42.05 | 9.46 | -33.65 | 26.84 | -5.95 | 13.41 | 5.56 | 56.69 | 50.25 | 53.54 | 40.99 | 29.39 | 19.43 | 19.36 | 15.84 | 12.17 | 10.00 | 7.56 | 4.22 | 2.24 | 2.07 |
EPS Diluted | 41.87 | 9.41 | -33.65 | 26.72 | -5.95 | 13.36 | 5.54 | 56.46 | 49.96 | 53.20 | 40.79 | 29.26 | 19.36 | 19.25 | 15.56 | 12.04 | 9.96 | 7.52 | 4.21 | 2.23 | 2.07 |
Weighted Avg Shares Out | 455.29M | 454.69M | 454.04M | 453.28M | 452.71M | 452.24M | 451.85M | 451.12M | 450.11M | 448.87M | 447.98M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M |
Weighted Avg Shares Out (Dil) | 457.23M | 456.95M | 454.04M | 455.24M | 452.71M | 454.12M | 453.33M | 452.97M | 452.78M | 451.71M | 450.24M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M |
Source: https://incomestatements.info
Category: Stock Reports